

Fig.2







Fig. 3





Key
 Carboplatin
 Docetaxel
 95% CI

Fig. 5






Fig. 6

a



<i>n</i> at risk (events)	Months from randomization								
	0	3	6	9	12				
C + Nonbasal	18	(9)	9	(5)	4	(2)	2	(2)	0
C + Basal	83	(44)	39	(15)	24	(16)	8	(3)	5
D + Nonbasal	18	(2)	16	(5)	11	(8)	3	(3)	1
D + Basal	87	(29)	58	(38)	20	(18)	2	(2)	1

b



<i>n</i> at risk (events)	Months from randomization								
	0	3	6	9	12				
C + 5NP	26	(15)	11	(6)	5	(2)	3	(3)	1
C + Core basal	67	(32)	35	(12)	23	(15)	8	(3)	5
D + 5NP	31	(8)	23	(10)	13	(10)	3	(3)	1
D + Core basal	65	(21)	44	(27)	17	(15)	2	(2)	1